TABLE 5

Anti-PRP antibody persistence (according-to-protocol cohorts for antibody persistence at 60 months after booster vaccination)

Group and time pointanb% with anti-PRP antibody levels of ≥0.15 μg/ml (95% CI)% with anti-PRP antibody levels of ≥1 μg/ml (95% CI)Anti-PRP antibody GMC (95% CI) (μg/ml)
Hib-MenC + PHiD-CV
    Postprimary13098.5 (94.6–99.8)97.7 (93.4–99.5)13.71 (11.11–16.93)
    Postbooster M1130100 (97.2–100)100 (97.2–100)90.53 (75.73–108.23)
    Postbooster M24121100 (97.0–100)93.4 (87.4–97.1)4.21 (3.41–5.21)
    Postbooster M36122100 (97.0–100)90.2 (83.4–94.8)3.76 (3.03–4.66)
    Postbooster M60130100 (97.2–100)84.6 (77.2–90.3)2.95 (2.40–3.62)
Hib-MenC + 7vCRM
    Postprimary132100 (97.2–100)97.0 (92.4–99.2)10.70 (8.87–12.90)
    Postbooster M1130100 (97.2–100)100 (97.2–100)65.65 (52.76–81.69)
    Postbooster M24125100 (97.1–100)84.8 (77.3–90.6)3.77 (3.04–4.69)
    Postbooster M3612599.2 (95.6–100)79.2 (71.0–85.9)2.80 (2.27–3.46)
    Postbooster M60132100 (97.2–100)75.8 (67.5–82.8)2.56 (2.07–3.17)
MenC-CRM
    Postprimary12798.4 (94.4–99.8)86.6 (79.4–92.0)4.23 (3.36–5.32)
    Postbooster M1127100 (97.1–100)99.2 (95.7–100)33.49 (27.11–41.37)
    Postbooster M24118100 (96.9–100)78.0 (69.4–85.1)2.51 (1.99–3.16)
    Postbooster M3612399.2 (95.6–100)67.5 (58.4–75.6)1.94 (1.56–2.41)
    Postbooster M6012799.2 (95.7–100)66.9 (58.0–75.0)1.66 (1.34–2.05)
MenC-TT
    Postprimary135100 (97.3–100)95.6 (90.6–98.4)6.48 (5.48–7.67)
    Postbooster M1134100 (97.3–100)100 (97.3–100)36.35 (30.22–43.73)
    Postbooster M24130100 (97.2–100)77.7 (69.6–84.5)2.29 (1.84–2.85)
    Postbooster M3612899.2 (95.7–100)62.5 (53.5–70.9)1.78 (1.42–2.24)
    Postbooster M6013498.5 (94.7–99.8)57.5 (48.6–66.0)1.65 (1.30–2.09)
  • a Postprimary, 1 month after the third dose at 6 months of age; postbooster M1, 1 month after booster vaccination; postbooster M24, approximately 24 months after booster vaccination; postbooster M36, approximately 36 months after booster vaccination; postbooster M60, approximately 60 months after booster vaccination.

  • b n, total number of children with available results.